• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Carisma Therapeutics, Inc. - Common Stock (NQ: CARM )

    0.9609 -0.0491 (-4.86%)
    Streaming Delayed Price Updated: 10:17 AM EDT, Sep 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 102,981
    Open 0.9797
    Bid (Size) 0.9609 (9)
    Ask (Size) 0.9851 (6)
    Prev. Close 1.010
    Today's Range 0.9549 - 1.010
    52wk Range 0.8000 - 4.860
    Shares Outstanding N/A
    Dividend Yield 37.57%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    CARM Stock Earnings: CARISMA Therapeutics Beats EPS, Beats Revenue for Q2 2024
    CARM stock results show that CARISMA Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Why Are Carisma Therapeutics Shares Surging Friday?
    Carisma Therapeutics Inc. (NASDAQ: CARM) shares are trading higher on Friday following the company's announcement of a significant development in its collaboration with Moderna. 
    Via Benzinga

    Performance

    YTD
    -66.17%
    -66.17%
    1 Month
    -10.20%
    -10.20%
    3 Month
    -42.46%
    -42.46%
    6 Month
    -54.02%
    -54.02%
    1 Year
    -77.55%
    -77.55%

    More News

    Read More
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    In-Depth Examination Of 5 Analyst Recommendations For CARISMA Therapeutics
    Via Benzinga
    The Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 Experts
    Via Benzinga
    The Latest Analyst Ratings for CARISMA Therapeutics
    Via Benzinga
    What 5 Analyst Ratings Have To Say About CARISMA Therapeutics
    Via Benzinga
    Analyst Ratings for CARISMA Therapeutics
    Via Benzinga
    CARM Stock Earnings: CARISMA Therapeutics Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    CARM Stock Earnings: CARISMA Therapeutics Beats EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    3 Top Under-$5 Stocks for Strong Gains and Positive Outlook
    Via InvestorPlace
    Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For October 3, 2023
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023
    Via Benzinga
    Steelcase, Commercial Metals And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Why Couchbase Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2023
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Via InvestorPlace
    Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2023
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Via InvestorPlace
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.